Pharmacokinetics of synthadotin (ILX651), a novel tubulin polymerization inhibitor, in patients with solid tumors
Peter L. Bonate, L. A. Hammond(Beth Israel Deaconess Medical Center), Elliot V. Hersh(University of Pennsylvania), A R Craig(Mary Crowley Cancer Research Center), Joseph P. Eder(Yale Cancer Center), Eric H. Rubin(Rutgers Cancer Institute), Akira Mita(Mary Crowley Cancer Research Center), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Casey Cunningham(Massachusetts General Hospital), Eric K. Rowinsky(The University of Texas at San Antonio)
Cited by 2
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k